CanaQuest Medical Corp has filed an International Cannabis/Botanical Patent which stems from its sponsored research program at Western University in London, Ontario, Canada.
The use of cannabis is known to cause neuronal, molecular and neuropsychiatric side effects. This complicates the use of cannabis for medical treatment.
THC is the primary psychoactive compound in cannabis and as demonstrated in both clinical and pre-clinical research, THC is associated with a wide range of damaging neuropsychiatric side-effects in both adolescent and adult users.
Chronic or acute THC exposure has been shown to increase anxiety, increase depressive symptoms, increase vulnerability to schizophrenia-related symptoms and to produce profound cognitive side effects such as deficits in cognitive filtering and memory impairments.
Given the increasing use of medical cannabis for the treatment of a wide variety of ailments, there is an urgent need for the development of a safer THC formulation that lacks the neurocognitive and neuropsychiatric side-effects.
Did you know that CanaQuest Medical Corp is a partner of Medical Cannabis Network? Discover CanaQuest’s medical cannabis formulations here.
Patent for THC formula
CanaQuest’s patented formulated THC product is called Mentabinol™, which treats various psychiatric disorders.
The application of Mentabinol in pre-clinical trials at Western University have demonstrated:
- Reversal of depression-like and schizophrenia related symptom effects;
- Complete blockage of memory impairment;
- Complete blockage of hyperactive activity; and
- Complete blockage of gene vulnerability.
The discovery was made by a research team led by Dr Steven Laviolette, the scientist at Western University in charge of one of the two sponsored research programs that CanaQuest currently has with prominent Canadian universities.
As research is ongoing, the patent represents the first patent in CanaQuest’s Master Platform of intellectual property in this field. CanaQuest is the sole owner of this medical discovery. Animal clinical trials have been completed, demonstrating promising results, and human trials are already designed and scheduled to begin soon.
Western University’s Dr Steven Laviolette said: “We are very excited by this unique discovery. Reducing the negative side effects of THC is an important step forward in developing more effective cannabinoid therapeutics.”
“We are continuing to work out the precise molecular mechanisms underlying the therapeutic modes of action for several unique cannabinoid formulations. These research projects are identifying safer and clinically superior cannabinoid formulations aimed at treating the symptoms of various psychiatric disorders, while eliminating the negative side effects associated with traditional marijuana formats.
“Our research projects have identified safer and clinically superior cannabinoid formulations aimed at treating the symptoms of various mental disorders.”
Paul Ramsay, Co-Founder and President of CanaQuest stated: “Our Patent is the foundation for real scientifically backed medical cannabis treatment for patients in need.”
CanaQuest are also entering discussions with domestic and international medical cannabis distributors.
The company’s competitive advantage comes from Intellectual Property developed under its sponsored research contract with Western University. The completed pre-clinical trials at the Western University lab has demonstrated exciting results and has put the company in a position to introduce CanaQuest’s novel THC formulation at the inception of the edible and extract marketplace.
Additionally, the scientific data and the beneficial results of CanaQuest’s proprietary CBD-based formulation is in the final stage and the company anticipates introduction of this new formulation into the marketplace in the very near future.
